Inventiva S.A. (IVA)
2.22
-0.10 (-4.31%)
At close: Jan 28, 2025, 2:23 PM
undefined% (undefined)
| Bid | 2.18 |
| Market Cap | 224.74M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.15 |
| PE Ratio (ttm) | -1.03 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.23 |
| Volume | 4,853 |
| Avg. Volume (20D) | 14,186 |
| Open | 2.25 |
| Previous Close | 2.32 |
| Day's Range | 2.15 - 2.28 |
| 52-Week Range | 1.53 - 4.50 |
| Beta | undefined |
About IVA
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype ...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 10, 2020
Employees 123
Stock Exchange NASDAQ
Ticker Symbol IVA
Website https://www.inventivapharma.com
Analyst Forecast
According to 4 analyst ratings, the average rating for IVA stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 574.52% from the latest price.
Buy 75.00%
Hold 25.00%
Sell 0.00%
5 days ago
+0%
Inventinva shares are trading higher after the com...
Unlock content with
Pro Subscription
3 months ago
+41.27%
Inventiva shares are trading higher after the company announced it raised up to €348 million to fund phase 3 NATiV3 clinical trial for MASH. Also, the company appointed a new chairman and director.
